RhoA	B:C0643681
/	O
Rock	O
Inhibition	O
Improves	O
the	O
Beneficial	O
Effects	O
of	O
Glucocorticoid	O
Treatment	O
in	O
Dystrophic	O
Muscle	I:C0026850
:	O
Implications	O
for	O
Stem	O
Cell	I:C0038250
Depletion	O
.	O

RhoA	O
/	O
Rock	B:C0389995
Inhibition	O
Improves	O
the	O
Beneficial	O
Effects	O
of	O
Glucocorticoid	O
Treatment	O
in	O
Dystrophic	O
Muscle	I:C0026850
:	O
Implications	O
for	O
Stem	O
Cell	I:C0038250
Depletion	O
.	O

RhoA	O
/	O
Rock	O
Inhibition	B:C2247986
Improves	O
the	O
Beneficial	O
Effects	O
of	O
Glucocorticoid	O
Treatment	O
in	O
Dystrophic	O
Muscle	I:C0026850
:	O
Implications	O
for	O
Stem	O
Cell	I:C0038250
Depletion	O
.	O

RhoA	O
/	O
Rock	O
Inhibition	O
Improves	O
the	O
Beneficial	O
Effects	O
of	O
Glucocorticoid	O
Treatment	O
in	O
Dystrophic	B:C0026850
Muscle	I:C0026850
:	O
Implications	O
for	O
Stem	O
Cell	I:C0038250
Depletion	O
.	O

RhoA	O
/	O
Rock	O
Inhibition	O
Improves	O
the	O
Beneficial	O
Effects	O
of	O
Glucocorticoid	O
Treatment	O
in	O
Dystrophic	O
Muscle	I:C0026850
:	O
Implications	O
for	O
Stem	B:C0038250
Cell	I:C0038250
Depletion	O
.	O

Glucocorticoid	O
treatment	O
represents	O
a	O
standard	O
palliative	B:C0030231
treatment	I:C0030231
for	O
Duchenne	O
muscular	I:C0013264
dystrophy	I:C0013264
(	O
Duchenne	O
muscular	I:C0013264
dystrophy	I:C0013264
)	O
patients	O
,	O
but	O
various	O
adverse	O
effects	I:C0879626
have	O
limited	O
this	O
treatment	O
.	O

Glucocorticoid	O
treatment	O
represents	O
a	O
standard	O
palliative	O
treatment	I:C0030231
for	O
Duchenne	B:C0013264
muscular	I:C0013264
dystrophy	I:C0013264
(	O
Duchenne	O
muscular	I:C0013264
dystrophy	I:C0013264
)	O
patients	O
,	O
but	O
various	O
adverse	O
effects	I:C0879626
have	O
limited	O
this	O
treatment	O
.	O

Glucocorticoid	O
treatment	O
represents	O
a	O
standard	O
palliative	O
treatment	I:C0030231
for	O
Duchenne	O
muscular	I:C0013264
dystrophy	I:C0013264
(	O
Duchenne	B:C0013264
muscular	I:C0013264
dystrophy	I:C0013264
)	O
patients	O
,	O
but	O
various	O
adverse	O
effects	I:C0879626
have	O
limited	O
this	O
treatment	O
.	O

Glucocorticoid	O
treatment	O
represents	O
a	O
standard	O
palliative	O
treatment	I:C0030231
for	O
Duchenne	O
muscular	I:C0013264
dystrophy	I:C0013264
(	O
Duchenne	O
muscular	I:C0013264
dystrophy	I:C0013264
)	O
patients	O
,	O
but	O
various	O
adverse	B:C0879626
effects	I:C0879626
have	O
limited	O
this	O
treatment	O
.	O

Glucocorticoid	O
treatment	O
represents	O
a	O
standard	O
palliative	O
treatment	I:C0030231
for	O
Duchenne	O
muscular	I:C0013264
dystrophy	I:C0013264
(	O
Duchenne	O
muscular	I:C0013264
dystrophy	I:C0013264
)	O
patients	O
,	O
but	O
various	O
adverse	O
effects	I:C0879626
have	O
limited	O
this	O
treatment	B:C0087111
.	O

In	O
an	O
effort	O
to	O
understand	O
the	O
mechanism	O
(s	O
)	O
by	O
which	O
glucocorticoids	B:C0017710
impart	O
their	O
effects	O
on	O
the	O
dystrophic	O
muscle	I:C0026850
,	O
and	O
potentially	O
reduce	O
the	O
adverse	O
effects	I:C0879626
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
prednisolone	O
treatment	O
in	O
dystrophin	O
/	O
utrophin	O
double	O
knockout	I:C0206745
(	I:C0206745
dKO	I:C0206745
)	I:C0206745
mice	I:C0206745
,	O
which	O
exhibit	O
a	O
severe	O
dystrophic	O
phenotype	O
due	O
to	O
rapid	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

In	O
an	O
effort	O
to	O
understand	O
the	O
mechanism	O
(s	O
)	O
by	O
which	O
glucocorticoids	O
impart	O
their	O
effects	O
on	O
the	O
dystrophic	B:C0026850
muscle	I:C0026850
,	O
and	O
potentially	O
reduce	O
the	O
adverse	O
effects	I:C0879626
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
prednisolone	O
treatment	O
in	O
dystrophin	O
/	O
utrophin	O
double	O
knockout	I:C0206745
(	I:C0206745
dKO	I:C0206745
)	I:C0206745
mice	I:C0206745
,	O
which	O
exhibit	O
a	O
severe	O
dystrophic	O
phenotype	O
due	O
to	O
rapid	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

In	O
an	O
effort	O
to	O
understand	O
the	O
mechanism	O
(s	O
)	O
by	O
which	O
glucocorticoids	O
impart	O
their	O
effects	O
on	O
the	O
dystrophic	O
muscle	I:C0026850
,	O
and	O
potentially	O
reduce	O
the	O
adverse	B:C0879626
effects	I:C0879626
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
prednisolone	O
treatment	O
in	O
dystrophin	O
/	O
utrophin	O
double	O
knockout	I:C0206745
(	I:C0206745
dKO	I:C0206745
)	I:C0206745
mice	I:C0206745
,	O
which	O
exhibit	O
a	O
severe	O
dystrophic	O
phenotype	O
due	O
to	O
rapid	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

In	O
an	O
effort	O
to	O
understand	O
the	O
mechanism	O
(s	O
)	O
by	O
which	O
glucocorticoids	O
impart	O
their	O
effects	O
on	O
the	O
dystrophic	O
muscle	I:C0026850
,	O
and	O
potentially	O
reduce	O
the	O
adverse	O
effects	I:C0879626
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
prednisolone	B:C0032950
treatment	O
in	O
dystrophin	O
/	O
utrophin	O
double	O
knockout	I:C0206745
(	I:C0206745
dKO	I:C0206745
)	I:C0206745
mice	I:C0206745
,	O
which	O
exhibit	O
a	O
severe	O
dystrophic	O
phenotype	O
due	O
to	O
rapid	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

In	O
an	O
effort	O
to	O
understand	O
the	O
mechanism	O
(s	O
)	O
by	O
which	O
glucocorticoids	O
impart	O
their	O
effects	O
on	O
the	O
dystrophic	O
muscle	I:C0026850
,	O
and	O
potentially	O
reduce	O
the	O
adverse	O
effects	I:C0879626
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
prednisolone	O
treatment	B:C0087111
in	O
dystrophin	O
/	O
utrophin	O
double	O
knockout	I:C0206745
(	I:C0206745
dKO	I:C0206745
)	I:C0206745
mice	I:C0206745
,	O
which	O
exhibit	O
a	O
severe	O
dystrophic	O
phenotype	O
due	O
to	O
rapid	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

In	O
an	O
effort	O
to	O
understand	O
the	O
mechanism	O
(s	O
)	O
by	O
which	O
glucocorticoids	O
impart	O
their	O
effects	O
on	O
the	O
dystrophic	O
muscle	I:C0026850
,	O
and	O
potentially	O
reduce	O
the	O
adverse	O
effects	I:C0879626
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
prednisolone	O
treatment	O
in	O
dystrophin	B:C1414083
/	O
utrophin	O
double	O
knockout	I:C0206745
(	I:C0206745
dKO	I:C0206745
)	I:C0206745
mice	I:C0206745
,	O
which	O
exhibit	O
a	O
severe	O
dystrophic	O
phenotype	O
due	O
to	O
rapid	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

In	O
an	O
effort	O
to	O
understand	O
the	O
mechanism	O
(s	O
)	O
by	O
which	O
glucocorticoids	O
impart	O
their	O
effects	O
on	O
the	O
dystrophic	O
muscle	I:C0026850
,	O
and	O
potentially	O
reduce	O
the	O
adverse	O
effects	I:C0879626
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
prednisolone	O
treatment	O
in	O
dystrophin	O
/	O
utrophin	B:C1421412
double	O
knockout	I:C0206745
(	I:C0206745
dKO	I:C0206745
)	I:C0206745
mice	I:C0206745
,	O
which	O
exhibit	O
a	O
severe	O
dystrophic	O
phenotype	O
due	O
to	O
rapid	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

In	O
an	O
effort	O
to	O
understand	O
the	O
mechanism	O
(s	O
)	O
by	O
which	O
glucocorticoids	O
impart	O
their	O
effects	O
on	O
the	O
dystrophic	O
muscle	I:C0026850
,	O
and	O
potentially	O
reduce	O
the	O
adverse	O
effects	I:C0879626
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
prednisolone	O
treatment	O
in	O
dystrophin	O
/	O
utrophin	O
double	B:C0206745
knockout	I:C0206745
(	I:C0206745
dKO	I:C0206745
)	I:C0206745
mice	I:C0206745
,	O
which	O
exhibit	O
a	O
severe	O
dystrophic	O
phenotype	O
due	O
to	O
rapid	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

In	O
an	O
effort	O
to	O
understand	O
the	O
mechanism	O
(s	O
)	O
by	O
which	O
glucocorticoids	O
impart	O
their	O
effects	O
on	O
the	O
dystrophic	O
muscle	I:C0026850
,	O
and	O
potentially	O
reduce	O
the	O
adverse	O
effects	I:C0879626
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
prednisolone	O
treatment	O
in	O
dystrophin	O
/	O
utrophin	O
double	O
knockout	I:C0206745
(	I:C0206745
dKO	I:C0206745
)	I:C0206745
mice	I:C0206745
,	O
which	O
exhibit	O
a	O
severe	O
dystrophic	B:C0026850
phenotype	O
due	O
to	O
rapid	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

In	O
an	O
effort	O
to	O
understand	O
the	O
mechanism	O
(s	O
)	O
by	O
which	O
glucocorticoids	O
impart	O
their	O
effects	O
on	O
the	O
dystrophic	O
muscle	I:C0026850
,	O
and	O
potentially	O
reduce	O
the	O
adverse	O
effects	I:C0879626
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
prednisolone	O
treatment	O
in	O
dystrophin	O
/	O
utrophin	O
double	O
knockout	I:C0206745
(	I:C0206745
dKO	I:C0206745
)	I:C0206745
mice	I:C0206745
,	O
which	O
exhibit	O
a	O
severe	O
dystrophic	O
phenotype	O
due	O
to	O
rapid	O
muscle	B:C0599856
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

Our	O
results	O
indicate	O
that	O
muscle	B:C0599856
stem	I:C0599856
cell	I:C0599856
depletion	O
in	O
double	O
knockout	I:C1522225
muscle	O
is	O
related	O
to	O
upregulation	O
of	O
mTOR	O
,	O
and	O
that	O
prednisolone	O
treatment	O
reduces	O
the	O
expression	O
of	O
mTOR	O
and	O
other	O
pro-inflammatory	O
mediators	I:C0574031
,	O
consequently	O
slowing	O
down	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

Our	O
results	O
indicate	O
that	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
in	O
double	B:C1522225
knockout	I:C1522225
muscle	O
is	O
related	O
to	O
upregulation	O
of	O
mTOR	O
,	O
and	O
that	O
prednisolone	O
treatment	O
reduces	O
the	O
expression	O
of	O
mTOR	O
and	O
other	O
pro-inflammatory	O
mediators	I:C0574031
,	O
consequently	O
slowing	O
down	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

Our	O
results	O
indicate	O
that	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
in	O
double	O
knockout	I:C1522225
muscle	B:C0026845
is	O
related	O
to	O
upregulation	O
of	O
mTOR	O
,	O
and	O
that	O
prednisolone	O
treatment	O
reduces	O
the	O
expression	O
of	O
mTOR	O
and	O
other	O
pro-inflammatory	O
mediators	I:C0574031
,	O
consequently	O
slowing	O
down	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

Our	O
results	O
indicate	O
that	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
in	O
double	O
knockout	I:C1522225
muscle	O
is	O
related	O
to	O
upregulation	B:C0041904
of	O
mTOR	O
,	O
and	O
that	O
prednisolone	O
treatment	O
reduces	O
the	O
expression	O
of	O
mTOR	O
and	O
other	O
pro-inflammatory	O
mediators	I:C0574031
,	O
consequently	O
slowing	O
down	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

Our	O
results	O
indicate	O
that	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
in	O
double	O
knockout	I:C1522225
muscle	O
is	O
related	O
to	O
upregulation	O
of	O
mTOR	B:C1447315
,	O
and	O
that	O
prednisolone	O
treatment	O
reduces	O
the	O
expression	O
of	O
mTOR	O
and	O
other	O
pro-inflammatory	O
mediators	I:C0574031
,	O
consequently	O
slowing	O
down	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

Our	O
results	O
indicate	O
that	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
in	O
double	O
knockout	I:C1522225
muscle	O
is	O
related	O
to	O
upregulation	O
of	O
mTOR	O
,	O
and	O
that	O
prednisolone	B:C0032950
treatment	O
reduces	O
the	O
expression	O
of	O
mTOR	O
and	O
other	O
pro-inflammatory	O
mediators	I:C0574031
,	O
consequently	O
slowing	O
down	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

Our	O
results	O
indicate	O
that	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
in	O
double	O
knockout	I:C1522225
muscle	O
is	O
related	O
to	O
upregulation	O
of	O
mTOR	O
,	O
and	O
that	O
prednisolone	O
treatment	B:C1533734
reduces	O
the	O
expression	O
of	O
mTOR	O
and	O
other	O
pro-inflammatory	O
mediators	I:C0574031
,	O
consequently	O
slowing	O
down	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

Our	O
results	O
indicate	O
that	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
in	O
double	O
knockout	I:C1522225
muscle	O
is	O
related	O
to	O
upregulation	O
of	O
mTOR	O
,	O
and	O
that	O
prednisolone	O
treatment	O
reduces	O
the	O
expression	B:C1171362
of	O
mTOR	O
and	O
other	O
pro-inflammatory	O
mediators	I:C0574031
,	O
consequently	O
slowing	O
down	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

Our	O
results	O
indicate	O
that	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
in	O
double	O
knockout	I:C1522225
muscle	O
is	O
related	O
to	O
upregulation	O
of	O
mTOR	O
,	O
and	O
that	O
prednisolone	O
treatment	O
reduces	O
the	O
expression	O
of	O
mTOR	B:C1447315
and	O
other	O
pro-inflammatory	O
mediators	I:C0574031
,	O
consequently	O
slowing	O
down	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

Our	O
results	O
indicate	O
that	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
in	O
double	O
knockout	I:C1522225
muscle	O
is	O
related	O
to	O
upregulation	O
of	O
mTOR	O
,	O
and	O
that	O
prednisolone	O
treatment	O
reduces	O
the	O
expression	O
of	O
mTOR	O
and	O
other	O
pro-inflammatory	B:C0574031
mediators	I:C0574031
,	O
consequently	O
slowing	O
down	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

Our	O
results	O
indicate	O
that	O
muscle	O
stem	I:C0599856
cell	I:C0599856
depletion	O
in	O
double	O
knockout	I:C1522225
muscle	O
is	O
related	O
to	O
upregulation	O
of	O
mTOR	O
,	O
and	O
that	O
prednisolone	O
treatment	O
reduces	O
the	O
expression	O
of	O
mTOR	O
and	O
other	O
pro-inflammatory	O
mediators	I:C0574031
,	O
consequently	O
slowing	O
down	O
muscle	B:C0599856
stem	I:C0599856
cell	I:C0599856
depletion	O
.	O

However	O
,	O
prednisolone	B:C0032950
treatment	O
was	O
unable	O
to	O
improve	O
the	O
myogenesis	O
of	O
stem	O
cells	I:C0038250
and	O
reduce	O
fibrosis	O
in	O
double	O
knockout	I:C1522225
muscle	O
.	O

However	O
,	O
prednisolone	O
treatment	B:C0087111
was	O
unable	O
to	O
improve	O
the	O
myogenesis	O
of	O
stem	O
cells	I:C0038250
and	O
reduce	O
fibrosis	O
in	O
double	O
knockout	I:C1522225
muscle	O
.	O

However	O
,	O
prednisolone	O
treatment	O
was	O
unable	O
to	O
improve	O
the	O
myogenesis	B:C0596997
of	O
stem	O
cells	I:C0038250
and	O
reduce	O
fibrosis	O
in	O
double	O
knockout	I:C1522225
muscle	O
.	O

However	O
,	O
prednisolone	O
treatment	O
was	O
unable	O
to	O
improve	O
the	O
myogenesis	O
of	O
stem	B:C0038250
cells	I:C0038250
and	O
reduce	O
fibrosis	O
in	O
double	O
knockout	I:C1522225
muscle	O
.	O

However	O
,	O
prednisolone	O
treatment	O
was	O
unable	O
to	O
improve	O
the	O
myogenesis	O
of	O
stem	O
cells	I:C0038250
and	O
reduce	O
fibrosis	B:C0016059
in	O
double	O
knockout	I:C1522225
muscle	O
.	O

However	O
,	O
prednisolone	O
treatment	O
was	O
unable	O
to	O
improve	O
the	O
myogenesis	O
of	O
stem	O
cells	I:C0038250
and	O
reduce	O
fibrosis	O
in	O
double	B:C1522225
knockout	I:C1522225
muscle	O
.	O

However	O
,	O
prednisolone	O
treatment	O
was	O
unable	O
to	O
improve	O
the	O
myogenesis	O
of	O
stem	O
cells	I:C0038250
and	O
reduce	O
fibrosis	O
in	O
double	O
knockout	I:C1522225
muscle	B:C0026845
.	O

We	O
then	O
studied	O
whether	O
glucocorticoid	O
treatment	O
can	O
be	O
improved	O
by	O
co-administration	B:C1533734
of	O
an	O
inhibitor	O
of	O
RhoA	O
/	O
ROCK	O
signaling	O
,	O
which	O
can	O
be	O
activated	O
by	O
glucocorticoids	O
and	O
was	O
found	O
in	O
our	O
previous	O
work	O
to	O
be	O
over	O
-	O
activated	O
in	O
dystrophic	O
muscle	I:C0026850
.	O

We	O
then	O
studied	O
whether	O
glucocorticoid	O
treatment	O
can	O
be	O
improved	O
by	O
co-administration	O
of	O
an	O
inhibitor	B:C1519313
of	O
RhoA	O
/	O
ROCK	O
signaling	O
,	O
which	O
can	O
be	O
activated	O
by	O
glucocorticoids	O
and	O
was	O
found	O
in	O
our	O
previous	O
work	O
to	O
be	O
over	O
-	O
activated	O
in	O
dystrophic	O
muscle	I:C0026850
.	O

We	O
then	O
studied	O
whether	O
glucocorticoid	O
treatment	O
can	O
be	O
improved	O
by	O
co-administration	O
of	O
an	O
inhibitor	O
of	O
RhoA	B:C0643681
/	O
ROCK	O
signaling	O
,	O
which	O
can	O
be	O
activated	O
by	O
glucocorticoids	O
and	O
was	O
found	O
in	O
our	O
previous	O
work	O
to	O
be	O
over	O
-	O
activated	O
in	O
dystrophic	O
muscle	I:C0026850
.	O

We	O
then	O
studied	O
whether	O
glucocorticoid	O
treatment	O
can	O
be	O
improved	O
by	O
co-administration	O
of	O
an	O
inhibitor	O
of	O
RhoA	O
/	O
ROCK	B:C0389995
signaling	O
,	O
which	O
can	O
be	O
activated	O
by	O
glucocorticoids	O
and	O
was	O
found	O
in	O
our	O
previous	O
work	O
to	O
be	O
over	O
-	O
activated	O
in	O
dystrophic	O
muscle	I:C0026850
.	O

We	O
then	O
studied	O
whether	O
glucocorticoid	O
treatment	O
can	O
be	O
improved	O
by	O
co-administration	O
of	O
an	O
inhibitor	O
of	O
RhoA	O
/	O
ROCK	O
signaling	B:C0037080
,	O
which	O
can	O
be	O
activated	O
by	O
glucocorticoids	O
and	O
was	O
found	O
in	O
our	O
previous	O
work	O
to	O
be	O
over	O
-	O
activated	O
in	O
dystrophic	O
muscle	I:C0026850
.	O

We	O
then	O
studied	O
whether	O
glucocorticoid	O
treatment	O
can	O
be	O
improved	O
by	O
co-administration	O
of	O
an	O
inhibitor	O
of	O
RhoA	O
/	O
ROCK	O
signaling	O
,	O
which	O
can	O
be	O
activated	O
by	O
glucocorticoids	B:C0017710
and	O
was	O
found	O
in	O
our	O
previous	O
work	O
to	O
be	O
over	O
-	O
activated	O
in	O
dystrophic	O
muscle	I:C0026850
.	O

We	O
then	O
studied	O
whether	O
glucocorticoid	O
treatment	O
can	O
be	O
improved	O
by	O
co-administration	O
of	O
an	O
inhibitor	O
of	O
RhoA	O
/	O
ROCK	O
signaling	O
,	O
which	O
can	O
be	O
activated	O
by	O
glucocorticoids	O
and	O
was	O
found	O
in	O
our	O
previous	O
work	O
to	O
be	O
over	O
-	O
activated	O
in	O
dystrophic	B:C0026850
muscle	I:C0026850
.	O

Our	O
results	O
indicate	O
that	O
the	O
combination	O
of	O
RhoA	B:C0643681
/	O
ROCK	O
inhibition	O
and	O
glucocorticoid	O
treatment	O
in	O
dystrophic	O
muscle	I:C0026850
have	O
a	O
synergistic	O
effect	O
in	O
alleviating	O
the	O
dystrophic	O
phenotype	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
combination	O
of	O
RhoA	O
/	O
ROCK	B:C0389995
inhibition	O
and	O
glucocorticoid	O
treatment	O
in	O
dystrophic	O
muscle	I:C0026850
have	O
a	O
synergistic	O
effect	O
in	O
alleviating	O
the	O
dystrophic	O
phenotype	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
combination	O
of	O
RhoA	O
/	O
ROCK	O
inhibition	B:C2247986
and	O
glucocorticoid	O
treatment	O
in	O
dystrophic	O
muscle	I:C0026850
have	O
a	O
synergistic	O
effect	O
in	O
alleviating	O
the	O
dystrophic	O
phenotype	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
combination	O
of	O
RhoA	O
/	O
ROCK	O
inhibition	O
and	O
glucocorticoid	O
treatment	O
in	O
dystrophic	B:C0026850
muscle	I:C0026850
have	O
a	O
synergistic	O
effect	O
in	O
alleviating	O
the	O
dystrophic	O
phenotype	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
combination	O
of	O
RhoA	O
/	O
ROCK	O
inhibition	O
and	O
glucocorticoid	O
treatment	O
in	O
dystrophic	O
muscle	I:C0026850
have	O
a	O
synergistic	O
effect	O
in	O
alleviating	O
the	O
dystrophic	B:C0026850
phenotype	O
.	O

Taken	O
together	O
,	O
our	O
study	O
not	O
only	O
shed	O
light	O
on	O
the	O
mechanism	O
by	O
which	O
glucocorticoid	B:C0017710
imparts	O
its	O
beneficial	O
effect	O
on	O
dystrophic	O
muscle	I:C0026850
,	O
but	O
also	O
revealed	O
the	O
synergistic	O
effect	O
of	O
RhoA	O
/	O
ROCK	O
inhibition	O
and	O
glucocorticoid	O
treatment	O
,	O
which	O
could	O
lead	O
to	O
the	O
development	O
of	O
more	O
efficient	O
therapeutic	O
approaches	I:C0087111
for	O
treating	O
Duchenne	O
muscular	I:C0013264
dystrophy	I:C0013264
patients	O
.	O

Taken	O
together	O
,	O
our	O
study	O
not	O
only	O
shed	O
light	O
on	O
the	O
mechanism	O
by	O
which	O
glucocorticoid	O
imparts	O
its	O
beneficial	O
effect	O
on	O
dystrophic	B:C0026850
muscle	I:C0026850
,	O
but	O
also	O
revealed	O
the	O
synergistic	O
effect	O
of	O
RhoA	O
/	O
ROCK	O
inhibition	O
and	O
glucocorticoid	O
treatment	O
,	O
which	O
could	O
lead	O
to	O
the	O
development	O
of	O
more	O
efficient	O
therapeutic	O
approaches	I:C0087111
for	O
treating	O
Duchenne	O
muscular	I:C0013264
dystrophy	I:C0013264
patients	O
.	O

Taken	O
together	O
,	O
our	O
study	O
not	O
only	O
shed	O
light	O
on	O
the	O
mechanism	O
by	O
which	O
glucocorticoid	O
imparts	O
its	O
beneficial	O
effect	O
on	O
dystrophic	O
muscle	I:C0026850
,	O
but	O
also	O
revealed	O
the	O
synergistic	O
effect	O
of	O
RhoA	B:C0643681
/	O
ROCK	O
inhibition	O
and	O
glucocorticoid	O
treatment	O
,	O
which	O
could	O
lead	O
to	O
the	O
development	O
of	O
more	O
efficient	O
therapeutic	O
approaches	I:C0087111
for	O
treating	O
Duchenne	O
muscular	I:C0013264
dystrophy	I:C0013264
patients	O
.	O

Taken	O
together	O
,	O
our	O
study	O
not	O
only	O
shed	O
light	O
on	O
the	O
mechanism	O
by	O
which	O
glucocorticoid	O
imparts	O
its	O
beneficial	O
effect	O
on	O
dystrophic	O
muscle	I:C0026850
,	O
but	O
also	O
revealed	O
the	O
synergistic	O
effect	O
of	O
RhoA	O
/	O
ROCK	B:C0389995
inhibition	O
and	O
glucocorticoid	O
treatment	O
,	O
which	O
could	O
lead	O
to	O
the	O
development	O
of	O
more	O
efficient	O
therapeutic	O
approaches	I:C0087111
for	O
treating	O
Duchenne	O
muscular	I:C0013264
dystrophy	I:C0013264
patients	O
.	O

Taken	O
together	O
,	O
our	O
study	O
not	O
only	O
shed	O
light	O
on	O
the	O
mechanism	O
by	O
which	O
glucocorticoid	O
imparts	O
its	O
beneficial	O
effect	O
on	O
dystrophic	O
muscle	I:C0026850
,	O
but	O
also	O
revealed	O
the	O
synergistic	O
effect	O
of	O
RhoA	O
/	O
ROCK	O
inhibition	B:C2247986
and	O
glucocorticoid	O
treatment	O
,	O
which	O
could	O
lead	O
to	O
the	O
development	O
of	O
more	O
efficient	O
therapeutic	O
approaches	I:C0087111
for	O
treating	O
Duchenne	O
muscular	I:C0013264
dystrophy	I:C0013264
patients	O
.	O

Taken	O
together	O
,	O
our	O
study	O
not	O
only	O
shed	O
light	O
on	O
the	O
mechanism	O
by	O
which	O
glucocorticoid	O
imparts	O
its	O
beneficial	O
effect	O
on	O
dystrophic	O
muscle	I:C0026850
,	O
but	O
also	O
revealed	O
the	O
synergistic	O
effect	O
of	O
RhoA	O
/	O
ROCK	O
inhibition	O
and	O
glucocorticoid	O
treatment	O
,	O
which	O
could	O
lead	O
to	O
the	O
development	O
of	O
more	O
efficient	O
therapeutic	B:C0087111
approaches	I:C0087111
for	O
treating	O
Duchenne	O
muscular	I:C0013264
dystrophy	I:C0013264
patients	O
.	O

Taken	O
together	O
,	O
our	O
study	O
not	O
only	O
shed	O
light	O
on	O
the	O
mechanism	O
by	O
which	O
glucocorticoid	O
imparts	O
its	O
beneficial	O
effect	O
on	O
dystrophic	O
muscle	I:C0026850
,	O
but	O
also	O
revealed	O
the	O
synergistic	O
effect	O
of	O
RhoA	O
/	O
ROCK	O
inhibition	O
and	O
glucocorticoid	O
treatment	O
,	O
which	O
could	O
lead	O
to	O
the	O
development	O
of	O
more	O
efficient	O
therapeutic	O
approaches	I:C0087111
for	O
treating	O
Duchenne	B:C0013264
muscular	I:C0013264
dystrophy	I:C0013264
patients	O
.	O

